Clinical Trial Update: A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for necitumumab in first-line treatment of stage IV squamous non-small cell lung cancer (Phase 1/2) completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• Necitumumab (necitumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Squamous Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-03-22